HCMHUTCHMED (China) Limited

HCM Stock Price, Valuation & Chart | HUTCHMED (China) Limited

$11.910-0.21 (-1.73%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic HCM intrinsic value HCM calculated fair value vs price

Overview Financials Dividends Ratios

HCM Historical price chart

HCM Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.08B

PE Ratio4.46

EPS2.67

Trading Volume74.51K

Today's High/Low12.14/11.89

Dividend Yield0.00

52 Week High/Low18.3/9.77

Shares Outstanding174.47M

HCM Financial Statement

HCM Analyst ratings

HCM Analysis & performance metrics

HCM Company profile

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and…

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC),…

HCM Management team

Name

Position

Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.ECTO

Company Secretary & Non-Executive Director

Wei-Guo Su B.Sc., Ph.D.CEO

Chief Executive Officer, Chief Scientific Officer & Executive Director

Charles George Rupert Nixon

Group General Counsel

Zhenping Wu M.B.A, Ph.D.

Executive Vice President of Pharmaceutical Science & Manufacturing

Qingmei Wang Ph.D.

Executive Vice President of Business Development & Strategic Alliances

Chig Fung Cheng BEc, CACFO

Chief Financial Officer & Executive Director

Yiling Cui

Executive Vice President & Head of Operations

David Ng

Head of Investor Relations & Capital Strategies

Name

Position

Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.ECTO

Company Secretary & Non-Executive Director

Wei-Guo Su B.Sc., Ph.D.CEO

Chief Executive Officer, Chief Scientific Officer & Executive Director

Charles George Rupert Nixon

Group General Counsel

Zhenping Wu M.B.A, Ph.D.

Executive Vice President of Pharmaceutical Science & Manufacturing

Qingmei Wang Ph.D.

Executive Vice President of Business Development & Strategic Alliances

Chig Fung Cheng BEc, CACFO

Chief Financial Officer & Executive Director

Yiling Cui

Executive Vice President & Head of Operations

David Ng

Head of Investor Relations & Capital Strategies

Management Team

Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.ECTO

Company Secretary & Non-Executive Director

Wei-Guo Su B.Sc., Ph.D.CEO

Chief Executive Officer, Chief Scientific Officer & Executive Director

Charles George Rupert Nixon

Group General Counsel

Zhenping Wu M.B.A, Ph.D.

Executive Vice President of Pharmaceutical Science & Manufacturing

Qingmei Wang Ph.D.

Executive Vice President of Business Development & Strategic Alliances

Chig Fung Cheng BEc, CACFO

Chief Financial Officer & Executive Director

Yiling Cui

Executive Vice President & Head of Operations

David Ng

Head of Investor Relations & Capital Strategies

Management

Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.ECTO

Company Secretary & Non-Executive Director

Wei-Guo Su B.Sc., Ph.D.CEO

Chief Executive Officer, Chief Scientific Officer & Executive Director

Charles George Rupert Nixon

Group General Counsel

Zhenping Wu M.B.A, Ph.D.

Executive Vice President of Pharmaceutical Science & Manufacturing

Qingmei Wang Ph.D.

Executive Vice President of Business Development & Strategic Alliances

Chig Fung Cheng BEc, CACFO

Chief Financial Officer & Executive Director

Yiling Cui

Executive Vice President & Head of Operations

David Ng

Head of Investor Relations & Capital Strategies

Total 8 executives

HCM Frequently asked questions

What is HUTCHMED (China) Limited (HCM) Stock Price?

Current stock price of HUTCHMED (China) Limited (HCM) stock is $11.910. The stock price is -1.73% lower in the session. The intraday range can be seen from this page. Volume of HUTCHMED (China) Limited (HCM) stock is 74.51K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the HUTCHMED (China) Limited (HCM) stock price going up or down today?

The stock price of HUTCHMED (China) Limited (HCM) can change with earnings, company news, and overall market sentiment. HUTCHMED (China) Limited operates in the Healthcare / Drug Manufacturers - Specialty & Generic market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the HUTCHMED (China) Limited stock expensive at its current price?

Whether HUTCHMED (China) Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for HCM on this page is 4.46. EPS on this page is 2.67. Compare those figures with peers and growth expectations before deciding if the current HUTCHMED (China) Limited price is justified.

How has the stock price of HUTCHMED (China) Limited (HCM) performed historically?

Historical performance for HUTCHMED (China) Limited (HCM) is shown on the price chart on this page. Review multi-period moves alongside volume to see how HCM reacted to past earnings and market events.

Should I buy HUTCHMED (China) Limited (HCM) stock, at this price?

Buying HUTCHMED (China) Limited (HCM) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.